Event-Driven Stocks

Dova Pharmaceuticals Inc.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs2 good2 warningdetails ↓

Financials

SEC XBRL · annual
 FY18FY17FY16
Revenue$0$0
Operating income−$13.7M−$5.2M−$5.2M
Net income−$13.8M−$5.4M−$5.2M
Total assets$112.2M$96.4M$28.7M
Total liabilities$35.8M$35.2M$22.0M
Equity$76.4M$61.2M$6.8M
EPS (diluted)
Shares out.25.7M25.7M17.3M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2018
Operating margin
Net margin
Return on equity
−18.0%
Return on assets
−12.3%
Return on capital (ROCE)
−14.8%
Liabilities / assets
31.9%
Debt / equity
0.47×
Book value / share
$2.97
Revenue growth (YoY)
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2018
Altman Z″ (distress)
3.06safe
Accruals / assets
35.6%high accruals
Piotroski F-Score
2/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
33
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 0Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

2 warning2 good
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Conservative leverage (liabilities < 50% of assets)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
0 acquisitions12 disposalsnet 17.1M shares · last 12
InsiderDateTypeSharesPrice
Perceptive Advisors Llc10% ownerNov 12, 2019J3.1M
Zaccardelli DavidOfficer — President &amp; CEONov 12, 2019D76,647
Wysenski NancyDirectorNov 12, 2019D6,274
Stalfort SeanDirectorNov 12, 2019U635,665$27.50
Novak Alfred JDirectorNov 12, 2019D6,901
Manning Paul BDirectorNov 12, 2019U13.0M$27.50
Laliberte KevinOfficer — Sr. VP, Product DevelopmentNov 12, 2019D4,761
Jeffs RogerDirectorNov 12, 2019D66,993
Hoitt JasonOfficer — Chief Commercial OfficerNov 12, 2019D9,970
Hahn Mark WOfficer — Chief Financial OfficerNov 12, 2019D9,024
Goldman Steven M.DirectorNov 12, 2019D144,280
Allen Lee F Md PhdOfficer — Chief Medical OfficerNov 12, 2019D9,635

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.